WO2011053892A1 - Synthèse et utilisation d'acides gras polyinsaturés à très longue chaîne (vlc-pufa) oméga-3 et oméga-6 - Google Patents

Synthèse et utilisation d'acides gras polyinsaturés à très longue chaîne (vlc-pufa) oméga-3 et oméga-6 Download PDF

Info

Publication number
WO2011053892A1
WO2011053892A1 PCT/US2010/054901 US2010054901W WO2011053892A1 WO 2011053892 A1 WO2011053892 A1 WO 2011053892A1 US 2010054901 W US2010054901 W US 2010054901W WO 2011053892 A1 WO2011053892 A1 WO 2011053892A1
Authority
WO
WIPO (PCT)
Prior art keywords
vlc
pufa
pufas
alcohol
acid
Prior art date
Application number
PCT/US2010/054901
Other languages
English (en)
Inventor
Krishna Raman
Vinod Tarwade
Norman Salem, Jr.
Original Assignee
Martek Biosciences Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martek Biosciences Corporation filed Critical Martek Biosciences Corporation
Publication of WO2011053892A1 publication Critical patent/WO2011053892A1/fr
Priority to US13/460,536 priority Critical patent/US20130190399A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/31—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/09—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis
    • C07C29/10—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis of ethers, including cyclic ethers, e.g. oxiranes
    • C07C29/103—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis of ethers, including cyclic ethers, e.g. oxiranes of cyclic ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/16—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/317—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
    • C07C67/327—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups by elimination of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers

Definitions

  • the invention relates to the synthesis of omega-3 and omega-6 very long chain
  • VLC- PUFAs polyunsaturated fatty acids
  • C28-C42:4, 5 and 6 polyunsaturated fatty acids
  • PUFAs Polyunsaturated fatty acids
  • PUFAs Polyunsaturated fatty acids
  • arachidonic acid (AA or ARA) has a chain length of 20 carbons and 4 double bonds beginning at the sixth carbon, and is referred to as "20:4 n-6.”
  • DHA docosahexaenoic acid
  • Another important LC-PUFA is eicosapentaenoic acid (EPA) which is designated (20:5 n-3).
  • n-3 and “omega-3” are used interchangeably as are the terms “n-6” and “omega-6.”
  • Other important PUFAs are the C-18 fatty acids, for example, linoleic (18:2 n-6), gamma- linolenic acid (18:3 n-6) in the n-6 pathway, and alpha-linolenic (18:3 n-3) and stearidonic (18:4 n-3) in the n-3 pathway.
  • These shorter PUFAs serve as precursors to the longer PUFAs in biosynthetic pathways that share elongation and desaturation steps and are well understood to those of skill in the art.
  • Omega-3 fatty acids include synthetic or naturally occurring omega-3 fatty acids, such as those found in fish oil, e.g., marine mammal (e.g., seal) fat, cod liver oil, walnuts and walnut oil, wheat germ oil, rapeseed oil, soybean lecithin, soybeans, tofu, common beans, butternuts, seaweed and flax seed oil.
  • An omega-3 fatty acid may also be derived from genetically engineered sources such as transgenic plants. Since the detection of DHA in the retina nearly forty years ago, extensive research efforts have documented its vital role in retinal physiology. In particular, multiple studies have shown that a baby milk formula which was deficient in DHA and its n-3 precursors delayed development of vision in neonates.
  • VLC PUFAs very long chain polyunsaturated fatty acids
  • VLC-PUFAs are at most a minor component of the human diet and, in mammalian systems, are believed to be synthesized by elongation of fatty acids including both omega- 3 and omega-6 PUFAs.
  • Synthesis of fatty acids up to C16 is catalyzed by the cytoplasmic fatty acid synthase complex and these fatty acids can be further elongated by the four consecutive enzymatic reactions shown in Figure 1. The first of these, condensation of a fatty acyl-CoA with malonyl-CoA, is catalyzed by one of seven known human elongases, each of which catalyzes substrate specific elongation of fatty acids of different lengths and degrees of saturation.
  • ELOVL4 is the elongase known to synthesize fatty acids with carbon chain lengths of 28 or longer. This enzyme has been shown to synthesize polyunsaturated C28-C36 fatty acids in the mouse retinal, and saturated and monounsaturated fatty acids in the mouse epidermis. The condensation of a fatty acyl-CoA with malonyl-CoA is the rate-limiting step of long chain fatty acid biosynthesis. ELOVL4 catalyzes this rate-limiting
  • VLC-PUFAs Conventional sources of VLC-PUFAs, such as retina, brain and sperm, have only extremely small amounts of these long chain fatty acids.
  • the present inventors have realized that the provision of compositions enriched in VLC-PUFAs would be of great benefit to human nutrition and health and would provide an alternative to the natural production or accumulation of these PUFAs by an organism.
  • the present inventors have therefore discovered alternative ways to produce these VLC-PUFAs for the preparation of compositions enriched in VLC-PUFAs that have significantly enhanced levels over naturally occurring tissue sources of VLC-PUFAs.
  • VLC-PUFAs omega-3 and omega-6 very long chain polyunsaturated fatty acids
  • C28-42:4,5 and 6 very long chain polyunsaturated fatty acids
  • derivatives and compositions containing these VLC-PUFAs that are particularly useful in the administration of VLC PUFAs for therapeutic purposes.
  • One aspect of the invention provides a method of coupling a long chain
  • hydrocarbon to an extender hydrocarbon in at least one step, to form a very long chain hydrocarbon having at least 28 carbon atoms.
  • a long chain hydrocarbon that has a displacement group on one end is contacted with an extending reagent, in at least one step, to form a very long chain hydrocarbon having at last 28 carbon atoms.
  • the long chain hydrocarbon starting material may be a C20 PUFA, such as ARA or EPA, or a C22 PUFA, such as DPA or DHA.
  • DHASCO-T and DHASCO-S oils may be used as a source of long chain hydrocarbon starting materials.
  • the extending reagent comprises an extender hydrocarbon chain with a
  • the extender hydrocarbon may be one of a C2, C4, C6, or C8 hydrocarbon.
  • the contacting of the long chain hydrocarbon with the extender hydrocarbon is conducted in the presence of an activating catalyst.
  • the protecting functional group is one of an ester or an ether.
  • nucleophillic acid in another embodiment of this aspect of the invention, the nucleophillic acid
  • displacement group is a halogen
  • the extending reagent is one of a Grignard extender reagent and a zinc extender reagent.
  • the protecting functional group is an ether
  • the ether formed in the coupling reaction is converted to an alcohol.
  • the alcohol is converted to a free fatty acid.
  • the free fatty acid is converted to an ester.
  • the free fatty acid is converted to an ethyl ester.
  • the protecting functional group is an ester
  • the ester formed in the coupling reaction is converted to a free fatty acid.
  • the free fatty acid is converted to an ethyl ester.
  • the VLC-PUFA has a chain length of 28, 30, 32, 34, 36, 38, 40 or 42 carbons.
  • the VLC-PUFA may be any one of the (C28-C42) n-3 fatty acids, including but not limited to, 28:4n3, 28:5n3, 28:6n3, 30:4n3, 30:5n3, 30:6n3, 32:4n3 32:5n3, 32:6n3, 34:4n3, 34:5n3, 34:6n3, 36:4n3, 36:5n3, 36:6n3, 38:4n3, 38:5n3, 38:6n3, 40:4n3, 40:5n3, 40:6n3, 42:4n3, 42:5n3, 42:6n3 and any one of the (C28-C40) n-6 fatty acids, including but not limited to, 28:3n6, 28:4n6, 28:5n6, 28:6n3, 30:4n3, 30:6n3, and any one of the (C28-C40) n-6 fatty
  • a related aspect is a composition containing at least one of these chemically-synthesized VLC-PUFAs. In certain embodiments, this composition contains greater than about 80% of a specific VLC- PUFA. In certain embodiments, this composition contains greater than about 90% of a specific VLC-PUFA.
  • VLC-PUFA alcohol has a chain length of 28, 30, 32, 34, 36, 38, 40 or 42 carbons.
  • the VLC-PUFA alcohol may be any one of the (C28-C42) n-3 fatty acids, including but not limited to, 28:4n3, 28:5n3, 28:6n3, 30:4n3, 30:5n3, 30:6n3, 32:4n3 32:5n3, 32:6n3, 34:4n3, 34:5n3, 34:6n3, 36:4n3, 36:5n3, 36:6n3, 38:4n3, 38:5n3, 38:6n3, 40:4n3, 40:5n3, 40:6n3, 42:4n3, 42:5n3, 42:6n3 and any one of the (C28-C40) n-6 fatty acids, including but not limited to, 28:3n6, 28:4n6, 28:5n6, 28:6n6, 30:4
  • this composition contains greater than about 80% of a specific VLC-PUFA alcohol. In certain embodiments, this composition contains greater than about 90% of a specific VLC-PUFA alcohol.
  • VLC-PUFA alcohol has a chain length of 28, 30, 32, 34, 36, 38, 40 or 42 carbons.
  • the VLC-PUFA alcohol may be any one of the (C28-C42) n-3 fatty alcohols, including but not limited to, 28:4n3, 28:5n3, 28:6n3, 30:4n3, 30:5n3, 30:6n3, 32:4n3 32:5n3, 32:6n3, 34:4n3, 34:5n3, 34:6n3, 36:4n3, 36:5n3, 36:6n3, 38:4n3, 38:5n3, 38:6n3, 40:4n3, 40:5n3, 40:6n3, 42:4n3, 42:5n3, 42:6n3 and any one of the (C28-C40) n-6 fatty alcohols , including but not limited to, 28:3n6, 28:4n6, 28:5
  • a related aspect is a composition containing at least one of these chemically- synthesized VLC-PUFA alcohols. In certain embodiments, this composition contains greater than about 80% of a specific VLC-PUFA alcohol. In certain embodiments, this composition contains greater than about 90% of a specific VLC-PUFA alcohol.
  • Another aspect of the invention is a VLC-PUFA free fatty acid.
  • the VLC-PUFA free fatty acid is a VLC-PUFA free fatty acid.
  • VLC-PUFA free fatty acid has a chain length of 28, 30, 32, 34, 36, 38, 40 or 42 carbons.
  • the VLC-PUFA free fatty acid may be any one of the (C28- C42) n-3 free fatty acids, including but not limited to, 28:4n3, 28:5n3, 28:6n3, 30:4n3, 30:5n3, 30:6n3, 32:4n3 32:5n3, 32:6n3, 34:4n3, 34:5n3, 34:6n3, 36:4n3, 36:5n3, 36:6n3, 38:4n3, 38:5n3, 38:6n3, 40:4n3, 40:5n3, 40:6n3, 42:4n3, 42:5n3, 42:6n3 and any one of the (C28-C40) n-6 free fatty acids, including but not limited to, 28:3n6, 28:4n6, 28:5n6, 28:6n6, 30:4n6, 30:5n6, 30:6n6, 32,
  • a related aspect is a composition containing at least one of these VLC-PUFA free fatty acid. In certain embodiments, this composition contains greater than about 80% of a specific VLC-PUFA free fatty acid. In certain embodiments, this composition contains greater than about 90% of a specific VLC-PUFA free fatty acid.
  • VLC-PUFA free fatty acid has a chain length of 28, 30, 32, 34, 36, 38, 40 or 42 carbons.
  • the VLC-PUFA free fatty acid may be any one of the (C28-C42) n-3 fatty acids, including but not limited to, 28:4n3, 28:5n3, 28:6n3, 30:4n3, 30:5n3, 30:6n3, 32:4n3 32:5n3, 32:6n3, 34:4n3, 34:5n3, 34:6n3, 36:4n3, 36:5n3, 36:6n3, 38:4n3, 38:5n3, 38:6n3, 40:4n3, 40:5n3, 40:6n3, 42:4n3, 42:5n3, 42:6n3 and any one of the (C28-C40) n-6 free fatty acids, including but not limited to, 28:3n6, 28:3n6, 28:3n6, 28:4n3, 30:5n3, 30:6n3, 30:6n3, 30:6n
  • a related aspect is a composition containing at least one of these chemically-synthesized VLC-PUFA free fatty acid. In certain embodiments, this composition contains greater than about 80% of a specific VLC-PUFA free fatty acid. In certain embodiments, this composition contains greater than about 90% of a specific VLC- PUFA free fatty acid.
  • VLC-PUFA ethyl ester has a chain length of 28, 30, 32, 34, 36, 38, 40 or 42 carbons.
  • the VLC-PUFA ethyl ester may be any one of the (C28-C42) n-3 ethyl esters, including but not limited to, 28:4n3, 28:5n3, 28:6n3, 30:4n3, 30:5n3, 30:6n3, 32:4n3 32:5n3, 32:6n3, 34:4n3, 34:5n3, 34:6n3, 36:4n3, 36:5n3, 36:6n3, 38:4n3, 38:5n3, 38:6n3, 40:4n3, 40:5n3, 40:6n3, 42:4n3, 42:5n3, 42:6n3 and any one of the (C28-C40) n-6 ethyl esters, including but not limited
  • this composition contains greater than about 80% of a specific VLC-PUFA ethyl ester. In certain embodiments, this composition contains greater than about 90% of a specific VLC-PUFA ethyl ester.
  • VLC-PUFA ethyl ester Another aspect of the invention is a chemically-synthesized VLC-PUFA ethyl ester.
  • the VLC-PUFA ethyl ester has a chain length of 28, 30, 32, 34, 36, 38, 40 or 42 carbons.
  • the VLC-PUFA ethyl ester may be any one of the (C28-C42) n-3 ethyl esters, including but not limited to, 28:4n3, 28:5n3, 28:6n3, 30:4n3, 30:5n3, 30:6n3, 32:4n3 32:5n3, 32:6n3, 34:4n3, 34:5n3, 34:6n3, 36:4n3, 36:5n3, 36:6n3, 38:4n3, 38:5n3, 38:6n3, 40:4n3, 40:5n3, 40:6n3, 42:4n3, 42:5n3, 42:6n3 and any one of the (C28-C40) n-6 ethyl esters, including but not limited to, 28:3n6, 28:4n6, 28:5n6, 28:6n6, 30:4n6, 30:5n6, 30:6n6, 32:4n6, 32:5n6, 32:6n6, 34:4n6, 34:5
  • a related aspect is a composition containing at least one of these chemically-synthesized VLC-PUFA ethyl ester. In certain embodiments, this composition contains greater than about 80% of a specific VLC-PUFA ethyl ester. In certain embodiments, this composition contains greater than about 90% of a specific VLC-PUFA ethyl ester.
  • VLC-PUFA trigylceride has a chain length of 28, 30, 32, 34, 36, 38, 40 or 42 carbons.
  • the VLC-PUFA triglyceride may be any one of the (C28-C42) n- 3 triglycerides, including but not limited to, 28:4n3, 28:5n3, 28:6n3, 30:4n3, 30:5n3, 30:6n3, 32:4n3 32:5n3, 32:6n3, 34:4n3, 34:5n3, 34:6n3, 36:4n3, 36:5n3, 36:6n3, 38:4n3, 38:5n3, 38:6n3, 40:4n3, 40:5n3, 40:6n3, 42:4n3, 42:5n3, 42:6n3 and any one of the (C28- C40) n-6 triglycerides, including but not limited to, 28:4n3, 28:5n3, 28:6n3, 30:4n3, 30:5n3, 30:6
  • a related aspect is a composition containing at least one of these VLC-PUFA triglyceride. In certain embodiments, this composition contains greater than about 80% of a specific VLC- PUFA triglyceride. In certain embodiments, this composition contains greater than about 90% of a specific VLC-PUFA triglyceride.
  • VLC-PUFA triglyceride Another aspect of the invention is a chemically-synthesized VLC-PUFA triglyceride.
  • the VLC-PUFA triglyceride has a chain length of 28, 30, 32,
  • the VLC-PUFA triglycerides may be any one of the (C28-C42) n-3 triglycerides, including but not limited to, 28:4n3, 28:5n3, 28:6n3, 30:4n3, 30:5n3, 30:6n3, 32:4n3 32:5n3, 32:6n3, 34:4n3, 34:5n3, 34:6n3, 36:4n3, 36:5n3, 36:6n3, 38:4n3, 38:5n3, 38:6n3, 40:4n3, 40:5n3, 40:6n3, 42:4n3, 42:5n3, 42:6n3 and any one of the (C28-C40) n-6 triglycerides, including but not limited to,
  • a related aspect is a composition containing at least one of these chemically-synthesized VLC-PUFA triglycerides. In certain embodiments, this composition contains greater than about 80% of a specific VLC-PUFA triglyceride. In certain embodiments, this composition contains greater than about 90% of a specific VLC- PUFA triglyceride.
  • VLC-PUFA phospholipid has a chain length of 28, 30, 32, 34, 36, 38, 40 or 42 carbons.
  • the VLC-PUFA phospholipid may be any one of the (C28-C42) n-3 phospholipids, including but not limited to, 28:4n3, 28:5n3, 28:6n3, 30:4n3, 30:5n3, 30:6n3, 32:4n3 32:5n3, 32:6n3, 34:4n3, 34:5n3, 34:6n3, 36:4n3, 36:5n3, 36:6n3, 38:4n3, 38:5n3, 38:6n3, 40:4n3, 40:5n3, 40:6n3, 42:4n3, 42:5n3, 42:6n3 and any one of the (C28- C40) n-6 phospholipids, including but not limited to, 28:3n6, 28:4n6, 28:5n6, 28:5n6, 28
  • a related aspect is a composition containing at least one of these VLC-PUFA phospholipid. In certain embodiments, this composition contains greater than about 80% of a specific VLC-PUFA phospholipid. In certain embodiments, this composition contains greater than about 90% of a specific VLC-PUFA ethyl ester.
  • VLC-PUFA ethyl ester has a chain length of 28, 30, 32, 34, 36, 38, 40 or 42 carbons.
  • the VLC-PUFA phospholipids may be any one of the (C28-C42) n-3 phospholipids, including but not limited to, 28:4n3, 28:5n3, 28:6n3, 30:4n3, 30:5n3, 30:6n3, 32:4n3 32:5n3, 32:6n3, 34:4n3, 34:5n3, 34:6n3, 36:4n3, 36:5n3, 36:6n3, 38:4n3, 38:5n3, 38:6n3, 40:4n3, 40:5n3, 40:6n3, 42:4n3, 42:5n3, 42:6n3 and any one of the (C28-C40) n-6 fatty acids, including but not limited to, 28:3n6, 28:4n6, 28:5n6, 28:6n6, 30:4n6, 30:5n6, 30:6n6, 32:4n6, 32:5n6, 32:6n6, 34:4n6, 34:5n6, 34:6n6, 36:4
  • a related aspect is a composition containing at least one of these chemically-synthesized VLC-PUFA phospholipids. In certain embodiments, this composition contains greater than about 80% of a specific VLC-PUFA phospholipid. In certain embodiments, this composition contains greater than about 90% of a specific VLC- PUFA phospholipid.
  • the composition is substantially free of at least one EPA and ARA.
  • some embodiments contain less than about 2%, less than about 1%, less than about 0.5%>, less than about 0.1 % or less than about 0.01%) of at least one of ARA and EPA.
  • the VLC-PUFA is provided substantially free of any other VLC-PUFAs.
  • some embodiments contain less than about 2%, less than about P/o, less than about 0.5%>, less than about 0.1 % or less than about O.O /o of any other VLC-PUFA.
  • Figure 1 shows the biosynthetic pathway leading to elongation of C16 fatty acids.
  • Figure 2 shows the MS/MS Spectrum of the DHA derived compound formed in the synthesis scheme described in Example 1.
  • Figure 3 shows the IR Spectrum of the DHA derived compound formed in the synthesis scheme described in Example 1.
  • Figure 4 shows A) LC-MS data and B) NMR data, for the C28:6 alcohol formed by the coupling reaction of DHA bromide with 6-tetrahydropyranyloxyhexyl magnesium chloride catalyzed by Li 2 CuCl 4 described in detail in Example 2.
  • Figure 5 shows the NMR data of the C28:6 bromide formed by bromination of the C28:6 described in detail in Example 2.
  • Figure 6 shows A) LC-MS data and B) NMR data, for the C34:6 alcohol formed in the coupling reaction of C28:6 bromide with 6-tetrahydropyranyloxyhexyl magnesium chloride catalyzed by Li 2 CuCl 4 and described in detail in Example 2.
  • Figure 7 shows the LC-MS data for C34:6 acid formed by oxidation of the C34:6 alcohol, as described in Example 2.
  • Figure 8 shows A) LC-MS data and B) NMR data, for the C34:6 ethyl ester formed from the esterification of C34:6 acid as described in Example 2.
  • Figure 9 shows A) LC-MS data and B) NMR data, for the C34:5 acid formed by the oxidation of C34:5 alcohol, as described in Example 3.
  • Figure 10 shows the NMR spectrum for the C34:5 ethyl ester by the esterification of the C34:5 acid as described in Example 3.
  • Figure 11 shows the HPLC-MS analysis of 34:6 and deuterated 3-34:5 (D3-C34:6), monitored selectively.
  • Figure 12 shows the HPLC-MS analysis of 34:5 and D3-34:5, monitored selectively.
  • Figure 13 shows the amount of 34:6 and 34:5 present in homogenates from rat livers taken from animals treated as described in Example 4.
  • the height of the bars represents the amount of analyte present in each sample (expressed as the ratio of the area of the chromatographic peak of a specific VLC-PUFA and its corresponding deuterated reference standard).
  • Figure 14 shows the amount of 34:6 and 34:5 present in homogenates from rat testis taken from animals treated as described in Example 4.
  • the VLC-PUFA is detected only in the experimental group that received the treatment.
  • Figure 15 shows the amount of 34:6 and 34:5 present in homogenates from rat eyes taken from animals treated as described in Example 4.
  • Figure 16 shows the determination of 34:6 and 34:5 levels in heart liver
  • Figure 17 shows the amount of 34:6 and 34:5 in samples obtained from blood withdrawn from test animals at different days of treatment.
  • the panel on the left shows data obtained from each of the four animals of the group treatment #3 (those who received 34:6 esters) at day 0, 1, 5 and 10 of the treatment.
  • the panel on the right shown data obtained from each of the four animal of experimental group #2 (those receiving 34:5 esters).
  • the invention provides chemical synthesis routes for the preparation of VLC-PUFAs starting with a source of docosahexaenoic acid (DHA) or docosapentaenoic acid (DPA).
  • DHA docosahexaenoic acid
  • DPA docosapentaenoic acid
  • DHASCO-T and DHASCO-S oils are used as the source of the DHA and DPA starting materials.
  • ethyl esters of DHA and DPAn6 are reduced to intermediate DHA and DPA alcohols that, on chemical oxidation, produce key intermediate aldehydes, such as docosahexaen-l-al.
  • An initial step in the production of very long chain polyunsaturated fatty acids of the invention is obtaining an ethyl ester of a fatty acid starting material.
  • a fatty acid starting material Several fatty acid ethyl esters are available commercially, but specifically desired ethyl esters may optionally be obtained by transesterification of a suitable source of PUFAs.
  • Transesterification methods of the present invention involve reacting a source of PUFA residues in the presence of an alcohol and a base to produce esters of the PUFAs.
  • One source of PUFAs are compositions containing triglycerides having PUFA residues. Suitable triglycerides contain at least one PUFA. In some embodiments, the PUFA has a chain length of at least 18 carbons. In some embodiments, the PUFA can be docosahexaenoic acid C22:6 n-3 (DHA), omega-3 docosapentaenoic acid C22:5 n-3 (DP A), omega-6 docosapentaenoic acid C22:5 n-6 (DP A), arachidonic acid C20:4 n-6 (ARA), eicosapentaenoic acid C20:5 n-3 (EPA), stearidonic acid (SDA), linolenic acid (LLA), alpha linolenic acid (ALA), gamma linolenic acid (GLA), conjugated linolenic acid (CLA) or mixtures thereof.
  • DHA docosa
  • the PUFAs can also be present in any of the common forms found in natural lipids including but not limited to triacylglycerols, diacylglycerols, monoacylglycerols, phospholipids, free fatty acids, ceramides, sphingomyelins and other glycolipid forms as well as in natural or synthetic derivative forms of these fatty acids (e.g. calcium salts of fatty acids, and the like).
  • Reference to an oil or other composition comprising triglycerides having PUFA residues can refer to either a composition comprising triglycerides having only a single type of PUFA residue such as DHA or a composition comprising triglycerides having a mixture of more than one type of PUFA residues such as more than one of DHA, EPA and ARA.
  • the following scheme shows the transesterification methods using a mixture of DHA and DPA PUFAs, such as DHASCO-STM oil (Martek, Columbia, MD).
  • compositions comprising triglycerides having PUFA residues can be obtained from, or derived from, any suitable source, such as a plant (including oilseeds), a microorganism, an animal, or mixtures of the foregoing.
  • the microorganisms can be algae, bacteria, fungi or protists. Microbial sources and methods for growing
  • microorganisms comprising nutrients and/or PUFAs are known in the art (Industrial Microbiology and Biotechnology, 2nd edition, 1999, American Society for Microbiology).
  • the microorganisms can be cultured in a fermentation medium in a fermentor. Oils produced by microorganisms can be used in the methods and
  • organisms include those selected from the group consisting of golden algae (such as microorganisms of the kingdom Stramenopiles), green algae, diatoms, dinoflagellates (such as microorganisms of the order Dinophyceae including members of the genus Crypthecodinium such as, for example, Crypthecodinium cohnii), yeast, and fungi of the genera Mucor and Mortierella, including but not limited to Mortierella alpina and Mortierella sect, schmuckeri.
  • golden algae such as microorganisms of the kingdom Stramenopiles
  • green algae diatoms
  • dinoflagellates such as microorganisms of the order Dinophyceae including members of the genus Crypthecodinium such as, for example, Crypthecodinium cohnii
  • yeast and fungi of the genera Mucor and Mortierella, including but not limited to Mortierella alpina and Mortierella sect, schmuckeri.
  • Stramenopiles include microalgae and algae-like microorganisms, including the following groups of microorganisms: Hamatores,
  • Pelagomonas Pelagococcus, Ollicola, Aureococcus, Parmales, Diatoms, Xanthophytes, Phaeophytes (brown algae), Eustigmatophytes, Raphidophytes, Synurids, Axodines (including Rhizochromulinaales, Pedinellales, Dictyochales), Chrysomeridales,
  • the Thraustochytrids include the genera Schizochytrium (species include aggregatum, limnaceum, mangrovei, minutum, octosporum), Thraustochytrium (species include arudimentale, aureum, benthicola, globosum, kinnei, motivum, multirudimentale, pachydermum, proliferum, roseum, striatum), Ulkenia (species include amoeboidea, kerguelensis, minuta, profunda, radiate, sailens, sarkariana, schizochytrops, visurgensis, yorkensis), Aplanochytrium (species include haliotidis, kerguelensis, profunda, stocchinoi), Japonochytrium (species include marinum), Althornia (species include crouchii),
  • Suitable microorganisms include those capable of producing lipids comprising omega-3 and/or omega-6 polyunsaturated fatty acids, and in particular microorganisms that are capable of producing oils containing DHA, DP A, EPA or ARA will be described. More particularly, the microorganisms may be algae, such as Thraustochytrids of the order Thraustochytriales, including Thraustochytrium (including Ulkenia) and Schizochytrium and including Thraustochytriales which are disclosed in U.S. Patent Nos. 5,340,594 and 5,340,742, both issued to Barclay, each of which are incorporated herein by reference in their entirety.
  • the microorganisms are selected from the group consisting of microorganisms having the identifying characteristics of ATCC number 20888, ATCC number 20889, ATCC number 20890, ATCC number 20891 and ATCC number 20892. Since there is some disagreement among experts as to whether Ulkenia is a separate genus from the genus Thraustochytrium, for the purposes of this application, the genus
  • Thraustochytrium will include Ulkenia. Also preferred are strains of Mortierella schmuckeri (e.g., including ATCC 74371) and Mortierella alpina. Also preferred are strains of Crypthecodinium cohnii, including microorganisms having the identifying characteristics of ATCC Nos. 30021, 30334-30348, 30541-30543, 30555-30557, 30571, 30572, 30772-30775, 30812, 40750, 50050-50060, and 50297-50300. Oleaginous microorganisms are also useful.
  • oleaginous microorganisms are defined as microorganisms capable of accumulating greater than 20% of the dry weight of their cells in the form of lipids.
  • Genetically modified microorganisms that produce PUFA- containing oils are also suitable for the present invention. These can include naturally PUFA-producing microorganisms that have been genetically modified as well as microorganisms that do not naturally produce PUFAs but that have been genetically modified to do so.
  • Suitable organisms can be obtained from a number of available sources, including by collection from the natural environment.
  • the American Type Culture Collection currently lists many publicly available strains of microorganisms identified above.
  • any organism, or any specific type of organism includes wild strains, mutants, or recombinant types. Growth conditions in which to culture or grow these organisms are known in the art, and appropriate growth conditions for at least some of these organisms are disclosed in, for example, U.S. Patent No. 5,130,242, U.S. Patent No. 5,407,957, U.S. Patent No. 5,397,591, U.S. Patent No. 5,492,938, U.S. Patent No. 5,711,983 and U.S. Patent No.
  • the microorganisms are cultured in an effective medium, herein defined as any medium capable of promoting oil production.
  • the effective medium also promotes rapid microbial growth.
  • the microorganisms can be cultured in conventional fermentation modes, which include, but are not limited to, batch, fed-batch, and continuous.
  • Another source of oils suitable for the transesterification methods of the present invention includes a plant source, such as oilseed plants.
  • PUFA-producing plants in alternate embodiments, can include those genetically engineered to express genes that produce PUFAs and those that produce PUFAs naturally. Such genes can include genes encoding proteins involved in the classical fatty acid synthase pathways, or genes encoding proteins involved in the PUFA polyketide synthase (PKS) pathway.
  • PPS PUFA polyketide synthase
  • Oilseed crops suitable for use in the present invention include soybeans, corn, rice, safflower, sunflower, canola, flax, peanut, mustard, rapeseed, chickpea, cotton, lentil, white clover, olive, palm oil, borage, evening primrose, linseed, and tobacco that have been genetically modified to produce a PUFA.
  • Alcohols suitable for use in the present invention include any lower alkyl alcohol containing from 1 to 6 carbon atoms (i.e., a Ci_ 6 alkyl alcohol).
  • Use of lower alkyl alcohols in the methods of the present invention produces lower alkyl esters of the PUFAs.
  • the use of ethanol produces ethyl esters.
  • the alcohol is methanol or ethanol.
  • the PUFA esters produced are a methyl ester and an ethyl ester of the PUFA, respectively.
  • the alcohol typically comprises between about 25 wt. % and about 50 wt. %; between about 30 wt. % and about 45 wt.
  • the alcohol comprises about 38 wt. % of the mixture of the composition, the alcohol and the base.
  • the composition and the base can be added to either pure ethanol or pure methanol.
  • the amount of alcohol used may vary with the solubility of the oil or composition containing triglycerides having PUFA residues in the alcohol.
  • Any base known in the art to be suitable for use as a reactant may be used in the present invention.
  • Bases of the formula RO-M, wherein M is a monovalent cation and RO is an alkoxide of a Ci_ 6 alkyl alcohol are particularly suited for the present invention.
  • Suitable bases include elemental sodium, sodium methoxide, sodium ethoxide, potassium methoxide, and potassium ethoxide.
  • the base is sodium ethoxide.
  • the base is typically added in an amount of between about 0.5 and about 1.5 molar equivalents of triglycerides, between about 0.7 and about 1.4 molar equivalents of triglycerides, between about 0.9 and about 1.3 molar equivalents of triglycerides, or between about 1.0 and about 1.2 molar equivalents of triglycerides to the reaction step with the composition and the alcohol.
  • the base is typically added in an amount of about 0.1 , 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 0.95, 1.0, 1.01 , 1.02, 1.03, 1.04, 1.05, 1.10, 1.15, 1.2, 1.3, 1.4, or 1.5 molar equivalents of triglycerides to the reaction step with the composition and the alcohol.
  • the base is added in an amount of 1.04 molar equivalents of triglycerides to the reaction step with the composition and the alcohol.
  • composition comprising triglycerides having polyunsaturated fatty acid residues, the alcohol and the base are reacted together at a temperature and for an amount of time that allows the production of an ester between the fatty acid residues and the alcohol. Suitable reaction times and temperatures may be determined by one of skill in the art to produce an ester. Without intending to be bound by theory, the PUFA residues are believed to be cleaved from the glycerol backbone of the triglyceride and esters of each PUFA residue are formed during the reacting step.
  • the step of reacting the composition in the presence of an alcohol and a base is performed at a temperature from about 60° C to about 120° C, from about 70° C to about 110° C, from about 75° C to about 100° C, or from about 80° C to about 90° C.
  • the step of reacting the composition in the presence of an alcohol and a base is performed at a temperature of about 75° C, 80° C, 85° C, 90° C, or 95° C. In some embodiments, the step of reacting the composition in the presence of an alcohol and a base is performed for a time from about 2 hours to about 12 hours, from about 3 hours to about 11 hours, from about 4 hours to about 10 hours, from about 5 hours to about 9 hours, or from about 6 hours to about 8 hours. In certain embodiments, the step of reacting the composition in the presence of an alcohol and a base is performed for about 5.5, 6, 6.5, 7, 7.5, 8, or 8.5 hours
  • the step of reacting the oil composition, alcohol and base may be conducted by refluxing the components to produce the PUFA esters.
  • the step of reacting the oil composition may be carried out at a temperature that does not result in the refluxing of the reaction components.
  • carrying out the step of reacting the oil composition under pressures greater than atmospheric pressure can increase the boiling point of the solvents present in the reaction mixture. Under such conditions, the reaction can occur at a temperature at which the solvents would boil at atmospheric pressure, but would not result in the refluxing of the reaction components.
  • the reaction is conducted at a pressure from about 5 to about 20 pounds per square inch (psi); from about 7 to about 15 psi; or from about 9 to about 12 psi.
  • the reaction is conducted at a pressure of about 7, 8, 9, 10, 11, or 12 psi. Reactions conducted under pressure may be carried out at the reaction
  • reactions conducted under pressure may be carried out at about 70° C, 75° C, 80° C, 85° C, or 90° C.
  • the reaction mixture comprising PUFA esters can be further processed to obtain the PUFA esters from the mixture.
  • the mixture may be cooled, diluted with water, and the aqueous solution extracted with a solvent such as hexane to produce a composition comprising PUFA esters.
  • Techniques for washing and/or extracting crude reaction mixtures are known in the art.
  • PUFA esters are separated from the reaction mixture by distilling the composition to recover a fraction comprising the ester of the polyunsaturated fatty acid. In this manner, a targeted fraction of the reaction mixture including PUFA esters of interest can be separated from the reaction mixture and recovered.
  • the distillation is performed under vacuum. Without being bound by theory, distillation under vacuum allows the distillation to be
  • Typical distillation temperatures range from about 120° C to about 170° C.
  • the step of distilling is performed at a temperature of less than about 180° C, less than about 175° C, less than about 170° C, less than about 165° C, less than about 160° C, less than about 155° C, less than about 150° C, less than about 145° C, less than about 140° C, less than about 135° C, or less than about 130° C.
  • Typical pressures for vacuum distillation range from about 0.1 mm Hg to about 10 mm Hg. In some embodiments, the pressure for vacuum distillation is about 0.1 , 0.5, 1 , 1.5, 2, 2,5, 3, 3.5, or 4 mm Hg.
  • compositions that contain a high percentage of PUFA esters.
  • such compositions can contain between about 50 wt. % and about 100 wt. % of an ester of a PUFA, and in other embodiments, the composition can comprise at least about 80 wt. %, at least about 85 wt. %, at least about 90 wt. %, at least about 95 wt. %, esters of a PUFA.
  • any residual water may be removed from the esters by, for example, washing the solvent with brine and/or passing the solvent over an anhydrous salt (e.g., sodium sulfate).
  • an anhydrous salt e.g., sodium sulfate
  • the solution then preferably is concentrated by, for example, evaporating a portion of the solvent.
  • the ethyl esters obtained commercially or produced by transesterification are reduced to produce intermediate alcohols.
  • the reduction of the esters to alcohols may take place under any suitable reducing conditions known to those of skill in the art. In a particular embodiment, the reduction takes place at about 0°C in the presence of lithium aluminum hydroxide (LAH) and tetrahydrofuran (THF). This reduction is shown in the following scheme using the example of DHA ethyl ester.
  • the intermediate alcohol is converted to a bromide intermediate, which is then coupled with a saturated magnesium Grignard extender reagent to produce an elongated VLC-PUFA of any desired length, the length being determined by the extender reagent used in this elongation reaction.
  • this extension reaction is conducted at 60 - 65 °C in the presence of the catalyst lithium chloride-copper chloride in a mixture of N-methyl pyrrolidone (NMP) and anhydrous tetrahydrofuran (THF).
  • NMP N-methyl pyrrolidone
  • THF anhydrous tetrahydrofuran
  • the resulting protected alcohol is de-protected in toluenesulfonic acid (TsOH) and methanol at room temperature, and washed with aqueous sodium bicarbonate.
  • the resulting alcohol may be oxidized to produce the free acid.
  • this is accomplished using the strong oxidant Periodic acid (H 5 I0 6 /Cr0 3 ) followed by a wash of cold acetonitrile and water.
  • Periodic acid H 5 I0 6 /Cr0 3
  • This extension reaction is illustrated in the following reaction scheme using the example of docosahexaen-l-ol (i.e. the alcohol derived from DHA) and 6-tetrahydropyranyloxyhexyl magnesium chloride to form a C28 intermediate.
  • the intermediate PUFA alcohols like docosahexaen-l-ol (i.e. the alcohol derived from DHA), are oxidized to produce intermediate aldehydes.
  • the oxidation of the alcohols to aldehydes may take place under any mild oxidizing conditions known to those of skill in the art. In a particular embodiment, the oxidation takes place at about -78°C in the presence of dimethyl sulfoxide (DMSO), oxalyl chloride and triethylamine (Et 3 N). This oxidation is shown in the following reaction scheme using the example of a DHA alcohol to form docosahexaen-l-al. OH
  • DMSO dimethyl sulfoxide
  • Et 3 N triethylamine
  • the intermediate aldehydes are coupled with a saturated zinc extender reagent to produce elongated VLC PUFAs of any desired length, the length being determined by the extender reagent used in this elongation reaction.
  • this extension reaction is conducted at about 0°C in the presence of the catalyst titanium isopropoxide (Ti (i-OPr) 4 ) in anhydrous tetrahydrofuran (THF).
  • Ti (i-OPr) 4 titanium isopropoxide
  • THF anhydrous tetrahydrofuran
  • the intermediate aldehydes are coupled with a saturated zinc extender reagent in the presence of a cupurate salt, to provide the elongated VLC PUFAs of any desired length, the length being determined by the extender reagent used in this elongation reaction.
  • this extension reaction is conducted at 0°C in the presence of CuCN ' 2 LiC, titanium isopropoxide (Ti(i-OPr) 4 ) in tetrahydrofuran (THF).
  • This extension reaction is illustrated in the following reaction scheme, which, similar to the elongation scheme shown above, uses docosahexaen-l-al (i.e.
  • an extended carbon chain ester intermediate is formed via halogenation of the primary alcohol.
  • the halogenated hydrocarbon is coupled with an aldehyde of any desired length to form the elongated ester.
  • the halogenation of the primary alcohol is conducted at about 0 °C using carbon tetrabromide, in the presence of triphenyl phosphene and methylene chloride.
  • the polyunsaturated fatty acid ester starting materials may be obtained commercially or prepared by transesterifiction of a source of mono-, di- or triglycerides. This coupling technique is illustrated in the following reaction scheme using the DHA ethyl ester starting material to form the C32 ester intermediate.
  • a zinc extending reagent is coupled with the halogenated hydrocarbon, which was created by halogenation of the reduced alcohol.
  • the halogenated hydrocarbon and the zinc extending reagent are coupled in the presence of a palladium catalyst to form an ester of desired length, followed by hydrolysis of the ester to form an elongated polyunsaturated fatty acid of the desired length.
  • This embodiment is illustrated in the following reaction scheme using DHA coupling with 6-Ethoxy-6-oxohexylzinc bromide followed by ester hydrolysis to form the C32 VLC PUFA.
  • ester intermediates of any of these embodiments may be converted to a VLC PUFA of the present invention by removing any alcohol and the ester moiety from the ester intermediate to form a fatty acid of at least 28 carbons in length.
  • the reduction of the secondary alcohol in the presence of diphenylsilane, followed by hydrolysis is shown in the following reaction scheme.
  • VLC PUFAs of the present invention are prepared and may be further purified for use in research or for administration to mammals for therapeutic purposes in a purified form or in pharmaceutically acceptable
  • VLC PUFAs of the present invention that are prepared using the synthesis methods of the present invention include:
  • VLC-PUFAs very long chain polyunsaturated fatty acids
  • VLC-PUFAs are defined as fatty acids of 26 and more carbon chain length, and are preferably fatty acids of 32 or more carbon chain length, and are more preferably fatty acids of 32-42 carbon chain length, containing 3 or more double bonds.
  • polyunsaturated fatty acid and “PUFA” include not only the free fatty acid form, but other forms as well, such as the triacylglycerol (TAG) form, the
  • phospholipid (PL) form the ethyl ester form and other esterified forms.
  • lipid includes phospholipids; free fatty acids; esters of fatty acids; triacylglycerols; diacylglycerides; monoacylglycerides; lysophospholipids; soaps; phosphatides; ceramides; sphingomyelins and other glycolipids, sterols and sterol esters; carotenoids; xanthophylls (e.g., oxycarotenoids); hydrocarbons; and other lipids known to one of ordinary skill in the art.
  • an analog refers to a chemical compound that is structurally similar to another compound but differs slightly in composition (as in the replacement of one atom by an atom of a different element or in the presence of a particular functional group, or the replacement of one functional group by another functional group).
  • an analog is a compound that is similar or comparable in function and appearance, but not in structure or origin to the reference compound.
  • the reference compound can be a reference VLC-PUFA, and an analog is a substance possessing a chemical structure or chemical properties similar to those of the reference VLC-PUFA.
  • substituted when used to describe a VLC-PUFA of the present invention, means that at least one hydrogen bound to the unsubstituted compound is replaced with a different atom or a chemical moiety.
  • substituents include, but are not limited to, hydroxy, alkyl, halogen, nitro, cyano, heterocycle, aryl, heteroaryl, amino, amide, ester, ether, carboxylic acid, thiol, thioester, thioether, sulfoxide, sulfone, carbamate, peptidyl, P0 3 H 2 , and mixtures thereof.
  • substituents include, but are not limited to, hydroxy, alkyl, halogen, nitro, cyano, heterocycle, aryl, heteroaryl, amino, amide, ester, ether, carboxylic acid, thiol, thioester, thioether, sulfoxide, sulfone, carbamate, peptidyl, P0 3 H 2 , and mixtures thereof.
  • a derivative has a similar physical structure to the parent compound, the derivative may have different chemical and/or biological properties than the parent compound.
  • Such properties can include, but are not limited to, increased or decreased activity of the parent compound, new activity as compared to the parent compound, enhanced or decreased bioavailability, enhanced or decreased efficacy, enhanced or decreased stability in vitro and/or in vivo, and/or enhanced or decreased absorbtion properties.
  • derivatives include esters, aldehydes and alcohols of the VLC- PUFAs of the present invention.
  • An example includes an ethyl ester of the VLC-PUFAs of the invention.
  • biologically active indicates that a compound has at least one detectable activity that has an effect on the metabolic or other processes of a cell or organism, as measured or observed in vivo (i.e., in a natural physiological environment) or in vitro (i.e., under laboratory conditions).
  • the therapeutically active VLC-PUFAs include the free, esterified, alcohol, oxygenated and aldehyde forms of these compounds.
  • One embodiment of the present invention relates to any compositions or formulations or products containing VLC-PUFAs, or analogs or derivatives thereof, as well as oils or other compositions or formulations or products that have been enriched for any VLC-PUFA or analogs or derivatives thereof, and particularly for any VLC-PUFA derived chemically from DHA, EPA, DPAn-6, ARA, DPAn-3 or DTAn-6, and more particularly, for any docosanoid, and even more particularly, for any PUFA derived from DHA or DPA or combinations of DHA and DPA.
  • the present invention also relates to any oils or other compositions or formulations or products in which such VLC-PUFAs are stabilized or retained in the oils or compositions to improve the quantity, quality or stability of the PUFAs in the oil or composition, and/or to improve the absorption, bioavailability, and/or efficacy of the PUFAs contained in oils or compositions.
  • DHA-, DP A- and EPA-derived PUFAs having anti-inflammatory activity, anti-proliferative activity, antioxidant activity, neuroprotective or vasoregulatory activity (Ye et al, 2002) are known. Additionally, as described above, VLC-PUFAs are expected to have efficacy in the prevention and treatment of disorders of the retina, including age related maculopathies, male fertility disorders, skin disorders, disorders of neurological development and neurodegenerative diseases.
  • Such PUFAs and VLC-PUFAs are encompassed by the present invention, particularly in embodiments where such VLC- PUFAs are enriched in oils and compositions, preferably using the synthetic methods and processing steps of the present invention, in combination with DHA-, DP A- and EPA- derived PUFAs.
  • Such compositions can be used in any therapeutic, nutritional (including nutraceutical), cosmetic, or other application. Therefore, the present invention
  • VLC-PUFAs encompasses isolated, semi-purified and purified VLC-PUFAs, as well as sources of PUFAs including synthesized and natural sources (e.g., oils or plants and portions thereof), and includes a VLC-PUFA useful in the present invention synthesized by processing steps as described herein.
  • the VLC-PUFAs and PUFAs in these compositions may be present as ethyl esters.
  • VLC-PUFAs may have either pro-inflammatory or anti-inflammatory properties.
  • pro-inflammatory properties are properties
  • cytokines e.g., interleukin-l (IL-l a), IL- ⁇ ⁇ , tumor necrosis factor-a (TNFa), IL-6, IL-8, IL-12, macrophage inflammatory protein- la (MIP-la), macrophage chemotactic protein- 1 (MCP-1 ; also known as macrophage/monocyte chemotactic and activating factor or monocyte chemoattractant protein- 1) and interferon- ⁇ (IFN- ⁇ )), eicosanoid production, histamine production, bradykinin production, prostaglandin production, leukotriene production, fever, edema or other swelling, and accumulation of cellular mediators (e.g., neutrophil
  • IL-l a interleukin-l
  • TNFa tumor necrosis factor-a
  • IL-6 tumor necrosis factor-a
  • IL-8 IL-12
  • MIP-la macrophage inflammatory protein- la
  • MIP-la macro
  • VLC-PUFA compounds, analogs or derivatives of the invention having a chiral center may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase) and how to determine anti-inflammatory activity, for example, using standard tests described herein, or using other similar tests which are well known in the art.
  • Prodrugs of any of the VLC-PUFAs described herein may be identified using routine techniques known in the art.
  • Various forms of prodrugs are known in the art.
  • prodrug derivatives see, for example, a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985); b) A Textbook of Drug Design and
  • the invention also includes solvates, metabolites, and salts (preferably pharmaceutically acceptable salts) of compounds of any of the VLC-PUFAs described herein.
  • solvate refers to an aggregate of a molecule with one or more solvent molecules.
  • a “metabolite” is a pharmacologically active product produced through in vivo metabolism in the body or organism of a specified compound or salt thereof. Such products may result for example from the oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, and the like, of the administered or produced compound.
  • the invention includes metabolites of any of the VLC-PUFAs or analogs or derivatives described herein, including compounds produced by a process comprising contacting a compound of this invention with an organism for a period of time sufficient to yield a metabolic product thereof.
  • a “pharmaceutically acceptable salt” or “salt” as used herein includes salts that retain the biological effectiveness of the free acids and bases of the specified compound and that are not biologically or otherwise undesirable.
  • a compound of the invention may possess a sufficiently acidic, a sufficiently basic, or both functional groups, and accordingly react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable sale.
  • Examples of pharmaceutically acceptable salts include those salts prepared by reaction of the compounds of the present invention with a mineral or organic acid or an inorganic base, such salts including sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyn-l,4-dioates, hexyne-l,6-dioates, benzoates, chlorobenzoates,
  • methylbenzoates dinitromenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, pheylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, . gamma. -hydroxybutyrates, glycollates, tartrates, methanesulfonates,
  • a single compound of the present invention may include more than one acidic or basic moieties, the compounds of the present invention may include mono, di or tri-salts in a single compound.
  • the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an acidic compound, particularly an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alphahydroxy acid, such as citric acid or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid, or
  • the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base.
  • inorganic salts are those formed with alkali and alkaline earth metals such as lithium, sodium, potassium, barium and calcium.
  • Particular organic base salts include, for example, ammonium, dibenzylammonium,
  • salts of acidic moieties may include, for example, those salts formed with procaine, quinine and N- methylglusoamine, plus salts formed with basic amino acids such as glycine, ornithine, histidine, phenylglycine, lysine and arginine.
  • Oils containing VLC-PUFAs described herein may be formed as oils in their free and/or esterifed forms.
  • the VLC-PUFAs can be present in the triglyceride, diglyceride, monoglyceride, phospholipid, sterol ester and/or wax ester forms. Since the VLC-PUFAs have only been described previously in the free fatty acid form, the esterified forms represent forms of VLC-PUFAs, the presence of which can be enhanced, stabilized or retained in oils or compositions of the present invention.
  • the VLC-PUFAs present in these oils are esterified, and more preferably, the VLC-PUFAs in these oils are present as ethyl esters.
  • oils and compositions according to the present invention may have
  • VLC-PUFA oils and compositions produced by the processes of the present invention will preferably contain at least 1 ⁇ g, at least 5 ⁇ g, at least 10 ⁇ g, at least 15 ⁇ g, at least 20 ⁇ g, at least 30 ⁇ g, at least 50 ⁇ g, at least 100 ⁇ g, at least 200 ⁇ g, at least 500 ⁇ g, at least 1,000 ⁇ g, at least 2,000 ⁇ g, at least 5,000 ⁇ g, at least 10,000 ⁇ g, or at least 50,000 ⁇ g or more of at least one or more ethyl esters of a VLC-PUFA per gram of oil (including any other increment in 0.1 ⁇ g increments).
  • the VLC-PUFA concentrations could actually be much higher ⁇ e.g., approaching 100%) during the production phase, although the oils and compositions would typically be diluted or titrated to the amounts described above, prior to being used in a nutritional, therapeutic, cosmetic or other process.
  • the oils and compositions of the present invention are formulated to contain a concentration of VLC-PUFAs or analogs or derivatives thereof that enables easy measurement and administration of a therapeutically-effective amount of these compounds.
  • the oils produced from the present invention are enriched with ethyl ester forms of VLC-PUFAs and may also include esters of DHA, and/or EPA and/or DPAn-3 and/or DPAn-6, and/or DTAn-6.
  • Oils, compositions, or pharmaceutical formulations (or any products) useful in the present invention preferably include VLC-PUFAs in an amount that is at least about 2 weight percent, or at least about 5 weight percent, or at least about 10 weight percent, or at least about 15 weight percent, or at least about 20 weight percent, or at least about 25 weight percent, or at least about 30 weight percent, or at least about 35 weight percent, or at least about 40 weight percent, or at least about 45 weight percent, or at least about 8050 weight percent, and so on, in increments of 1 weight percent (i.e., 2, 3, 4, 5,...) up to or at least about 90 weight percent or more, or up to at least about 95 weight percent or higher of the total lipids in the oil, composition of formulation.
  • VLC-PUFAs in an amount that is at least about 2 weight percent, or at least about 5 weight percent, or at least about 10 weight percent, or at least about 15 weight percent, or at least about 20 weight percent, or at least about 25 weight percent, or at least about 30 weight percent, or at least about 35
  • the oil, composition, formulation or other product comprises a therapeutically-effective amount of a VLC-PUFA or analog or derivative in combination with DPAn-6 and/or DHA.
  • the amount of the VLC-PUFA or analog or derivative may represent about 30 weight percent or more, about 35 weight percent or more, about 40 weight percent or more, about 45 weight percent or more, about 50 weight percent or more, about 55 weight percent or more, about 60 weight percent or more, about 65 weight percent or more, about 70 weight percent or more, about 75 weight percent or more, or about 80 weight percent or more, or about 85 weight percent or more, or about 90 weight percent or more, or about 95 weight percent or more of the composition of the VLC-PUFA with DPAn-6 and/or DHA.
  • the ratio of VLC-PUFA to DHA or DPA (n-6) in the oil, composition, formulation or other product is between about 1 : 10 to about 10 : 1 , or any ratio between 1 :10 and 10: 1.
  • the VLC-PUFAs and/or derivatives thereof that are used in oils, supplements, cosmetics, infant formulas, therapeutic and pharmaceutical compositions, and other formulations or products described herein, may be provided in a variety of forms.
  • such forms include, but are not limited to, esters of the VLC-PUFAs; free fatty acids; alcohols; aldehydes; conjugates of the VLC- PUFAs with another bioactive molecule; and combinations thereof.
  • the VLC- PUFAs present in these formulations or products are present as ethyl esters.
  • VLC-PUFAs can be blended with long chain fatty acids in amounts and/or ratios that are different from the amounts or ratios that occur in natural sources of the fatty acids, such as by blending, purification, or enrichment. These forms allow flexibility in the formulation of foods with high sensory quality, dietary or nutritional supplements, and pharmaceutical agents.
  • any biologically acceptable dosage forms, and combinations thereof, are within the compositions of the invention.
  • dosage forms include, without limitation, chewable tablets, quick dissolve tablets, effervescent tablets, reconstitutable powders, elixirs, liquids, solutions, suspensions, emulsions, tablets, multi-layer tablets, bi- layer tablets, capsules, soft gelatin capsules, hard gelatin capsules, caplets, lozenges, chewable lozenges, beads, powders, granules, particles, microparticles, dispersible granules, cachets, douches, suppositories, creams, topicals, inhalants, aerosol inhalants, patches, particle inhalants, implants, depot implants, ingestibles, injectables, infusions, health bars, confections, cereals, cereal coatings, foods, nutritive foods, functional foods and combinations thereof.
  • Particular dosage formulations include hard or soft gelatin capsules encapsulating an oil having a therapeutically-effective amount of one or more
  • a food that is enriched with the desired VLC- PUFA and/or VLC-PUFA derivatives thereof, is selected from the group including, but not limited to: baked goods and mixes; chewing gum; cereals; cheese products; nuts and nut-based products; gelatins, pudding, and fillings; frozen dairy products; milk products; dairy product analogs; hard or soft candy; soups and soup mixes; snack foods; processed fruit juice; processed vegetable juice; fats and oils; fish products; plant protein products; poultry products; and meat products.
  • oils containing VLC-PUFAs, and derivatives thereof will be useful as dietary supplements or therapeutically-effective pharmaceutical compositions in the form of oil-filled capsules or through fortification of foods, beverages or infant formula to enhance the anti-inflammatory benefits of these products.
  • the VLC-PUFAs are provided for delivery in a single dietary supplement.
  • foods and beverages including, but not limited to, dairy products and dairy analogs, bakery products and confectionaries, processed meats and meat analogs, grain products and cereals, liquid and powered beverages, including juices and juice drinks, carbonated and processed beverage products or infant formulas may be fortified with VLC-PUFA oils.
  • VLC-PUFA oils may be microencapsulated prior to fortification of the foods, beverages or formulas to reduce oxidation/degradation of the VLC-PUFAs and to improve organoleptic properties and shelf-life of the fortified food/beverage or infant formula products.
  • VLC-PUFAs may be formulated into a cream or emulsion for topical applications for preventing or treating skin disorders, including the reduction of inflammation.
  • the VLC-PUFAs may be formulated into sun screens or cosmetics, such as face or hand creams, moisturizers, foundations, eye gels or shaving creams, to reduce skin irritation or redness, allergic reactions or edema.
  • VLC-PUFAs and in particular VLC-PUFA-rich oils are used in pharmaceutical formulations to prevent or reduce symptoms of conditions or diseases of the eye, and especially the retina, testis or brain.
  • the VLC-PUFAs are administered to a mammal in need of such compounds in the form of a liquid, suspension, emulsion, oil or ointment applied to the eye or eye lids in order to target delivery of these VLC-PUFAs, or analogs or derivatives thereof, to the eye(s) of the mammal.
  • PUFAs and/or VLC-PUFA derivatives thereof can be provided with one or more additional components that may be useful in a therapeutic treatment method of the invention.
  • additional components include, but are not limited to, any additional anti-inflammatory agent, nutritional supplement (e.g., vitamins, minerals and other nutritional agents, including nutraceutical agents), a therapeutic agent, or a pharmaceutical or a nutritional carrier (e.g., any excipient, diluent, delivery vehicle or carrier compounds and formulations that can be used in conjunction with pharmaceutical (including therapeutic) compositions or nutritional compositions).
  • One embodiment of the present invention is based on the use of VLC-PUFAs and/or the VLC-PUFA analogs or derivatives, and/or oils or pharmaceutical compositions that have been enriched for VLC-PUFAs to provide cardiovascular, anti-inflammatory, neuroprotective, fertility-enhancing and/or disease prevention effects in humans and other animals. Such effects are useful for enhancing the general health of an individual, as well as in treating or preventing a variety of diseases and conditions in an individual.
  • one embodiment of the present invention relates to the use of: (1) a VLC-PUFA or VLC-PUFA derivative alone or in combination with other PUFAs and/or other PUFA derivatives; and/or (2) an oil or product produced using such oil, wherein the oil has been enriched in quantity, quality and/or stability of the VLC-LCPUFAs contained therein.
  • the use of these compositions is typically provided by an oil or product using such oil, a nutritional supplement, cosmetic formulation or pharmaceutical composition (medicament or medicine).
  • Cardiovascular risk factors may include high blood pressure, elevated serum cholesterol, cigarette smoking, obesity, glucose intolerance, diabetes, left ventricular hypertrophy, low HDL cholesterol, lack of exercise, excessive alcohol intake, and/or high fibrinogen levels.
  • Such oils, supplements, compositions and formulations can be used for the reduction of inflammation in a patient that has or is at risk of developing inflammation or a disease or condition associated with inflammation.
  • Symptoms of inflammation include both physiological and biological symptoms including, but are not limited to, cytokine production, eicosanoid production, histamine production, bradykinin production, prostaglandin production, leukotriene production, fever, edema or other swelling, pain (e.g., headaches, muscle aches, cramps, joint aches), chills, fatigue/loss of energy, loss of appetite, muscle or joint stiffness, redness of tissues, fluid retention, and accumulation of cellular mediators (e.g., neutrophils, macrophages, lymphocytes, etc.) at the site of inflammation.
  • Diseases associated with inflammation include, but are not limited to, conditions associated with infection by infectious agents (e.g., bacteria, viruses), shock, ischemia, cardiopulmonary diseases, autoimmune diseases, neurodegenerative conditions, and allergic inflammatory conditions, and
  • Such oils, supplements, compositions and formulations can also be used for the reduction of any symptoms related to neurodegeneration or a disease associated with neurodegeneration in a patient that has or is at risk of developing a neurodegenerative condition or disease.
  • Symptoms associated with neurodegeneration include both physiological and biological symptoms including, but not limited to: neurodegeneration, intellectual decline, behavioral disorders, sleep disorders, common medical complications, dementia, psychosis, anxiety, depression, inflammation, pain, and dysphagia.
  • Such oils, supplements, compositions and formulations can also be used for the reduction of any symptoms related to macular degeneration or a disease associated with macular degeneration in a patient that has or is at risk of developing a degenerative eye condition or disease including Stargardt disease.
  • Symptoms associated with macular degeneration may include blurred vision, a gradual loss of central vision or a rapid onset of vision loss, central scotomas (shadows or missing areas of vision), distorted vision (i.e. metamorphopsia), trouble discerning colors, slow recovery of visual function after exposure to bright light, and loss in contrast sensitivity.
  • Such oils, supplements, compositions and formulations can also be used to enhance fertility or treat a disease associated with a fertility disorder, particularly regarding sperm motility or disorders of the testes, in a patient that has or is at risk of developing a fertility disorder or condition or disease, such that increasing the VLC-PUFA content of sperm cells leads to the enhanced production of viable, mature sperm cells.
  • Symptoms associated with disorders of fertility may include decreased or aberrant sperm motility, viability or cold sensitivity within fresh or stored ejaculates.
  • the compositions and method of the present invention preferably protect the patient from inflammation, neurodegeneration, macular or retinal degeneration, fertility disorders or a condition or disease associated with inflammation.
  • the phrase "protected from a disease” refers to reducing the symptoms of the disease; reducing the occurrence of the disease, and/or reducing the severity of the disease.
  • Protecting a patient can refer to the ability of a nutritional or therapeutic composition of the present invention, when administered to the patient, to prevent inflammation from occurring and/or to cure or to alleviate inflammation and/or disease/condition symptoms, signs or causes.
  • to protect a patient from a disease or condition includes both preventing occurrence of the disease or condition (prophylactic treatment) and treating a patient that has a disease or condition or that is experiencing initial symptoms of a disease or condition (therapeutic treatment).
  • disease or “condition” refers to any deviation from the normal health of an animal and includes a state when disease symptoms are present, as well as conditions in which a deviation (e.g., infection, gene mutation, genetic defect, etc.) has occurred, but symptoms are not yet manifested.
  • a deviation e.g., infection, gene mutation, genetic defect, etc.
  • the VLC-PUFAs (or analogs or derivatives thereof), compositions comprising such VLC-PUFAs, and methods of the invention, are suitable for use in any individual (subject) that is a member of the Vertebrate class, Mammalia, including, without limitation, primates, livestock and domestic pets (e.g., a companion animal). Most typically, an individual will be a human. According to the present invention, the terms "patient”, “individual” and “subject” can be used
  • an individual to which an PUFA(s) or composition or formulation or oil of the present invention can be administered includes an individual who is at risk of, diagnosed with, or suspected of having
  • Individuals can also be healthy individuals, wherein VLC-PUFAs or compositions of the invention are used to enhance, maintain or stabilize the health of the individual.
  • the amount of a VLC-PUFA or VLC-PUFA derivative to be administered to a individual can be any amount suitable to provide the desired result of reducing at least one symptom of inflammation, neurodegeneration, or eye disorder or protecting the individual from a condition or disease associated with such disorders.
  • a VLC- PUFA is administered in a dosage of from about 0.1 mg of the VLC-PUFA per kg body weight of the individual to about 500mg of the PUFA per kg body weight of the individual, although dosages are not limited to these amounts.
  • a VLC-PUFA derivative or mixture of such derivatives is administered in a dosage of from about 0.2 ⁇ g of the PUFA per kg body weight of the individual to about 100 mg of the derivative(s) per kg body weight of the individual, although dosages are not limited to these amounts.
  • the VLC-PUFAs formulated as pharmaceutical compositions are effective over a wide dosage range and are administered in a therapeutically-effective amount.
  • the dosage and manner of administration will be defined by the application of VLC-PUFA and can be determined by routine methods of clinical testing to find the optimum dose.
  • the amount of the pharmaceutical compositions and formulations actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
  • compositions and formulations of the invention can be administered topically or as an injectable, the oral or ocular routes of administration are also useful.
  • the compositions and formulations used herein may be administered to subjects in the form of nutritional supplements and/or foods (including food products) and/or
  • additional agents can be included in the compositions when administered or provided to the subject, such as other antiinflammatory agents, vitamins, minerals, carriers, excipients, and other therapeutic agents.
  • additional agent is aspirin, or another suitable anti-inflammatory agent.
  • a food product that is enriched with the desired VLC-PUFAs and/or PUFA derivatives thereof may include, but is not limited to: baked goods and mixes; chewing gum; breakfast cereals; cheese products; nuts and nut-based products; gelatins, pudding, and fillings; frozen dairy products; milk products; dairy product analogs; hard or soft candy; soups and soup mixes; snack foods; processed fruit juice; processed vegetable juice; fats and oils; fish products; plant protein products; poultry products; and meat products.
  • oils containing VLC-PUFAs and VLC-PUFA derivatives may be useful as dietary supplements in the form of oil-filled capsules or through fortification of foods, beverages or infant formula.
  • compositions of the present invention contain, as the active ingredient, one or more of the VLC-PUFAs, associated with pharmaceutically acceptable formulations.
  • the VLC-PUFAs are present in these pharmaceutically acceptable formulations.
  • compositions as esters More preferably, the VLC-PUFAs are present in these
  • compositions as ethyl esters.
  • the active ingredient is usually mixed with an excipient, diluted by an excipient or enclosed within a carrier which can be in the form of a capsule, paper or other container.
  • An excipient is usually an inert substance that forms a vehicle for a drug.
  • the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
  • the compositions can be in the form of solutions, syrups, suspensions, ointments, creams, soft and hard gelatin capsules, suppositories, and injectable solutions, such as parenteral nutrition preparations for injection.
  • excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, gum Arabic, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methylcellulose.
  • the formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates;
  • compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
  • the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
  • a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
  • the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above.
  • Formulations of the invention suitable for oral administration may be in the form of capsules, pills, tablets, or as a solution or a suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsions, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia), and the like, each containing a predetermined amount of a VLC-PUFA of the present invention as an active ingredient.
  • the active ingredient is mixed with one or more pharmaceutically acceptable carriers, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monosterate;
  • fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid
  • compositions may also include buffering agents.
  • Solid compositions of a similar type may be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
  • Liquid dosage forms for oral administration of the VLC-PUFAs of the invention include pharmaceutically-acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral formulations may also include
  • Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • a suppository which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
  • suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
  • Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
  • Dosage forms for the topical or transdermal administration of the VLC-PUFAs of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, drops and inhalants.
  • the active VLC-PUFA ingredient may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any buffers, or propellants which may be required.
  • the ointments, pastes, creams and gels may contain, in addition to an active VLC-PUFA ingredient, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Powders and sprays can contain, in addition to an active ingredient, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder or mixtures of these substances.
  • Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
  • Transdermal patches have the added advantage of providing controlled delivery of VLC-PUFAs to the skin or body.
  • dosage forms can be made by dissolving, dispersing or otherwise incorporating one or more VLC-PUFA compounds in a proper medium, such as an elastomeric matrix material.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin.
  • the rate of such flux can be controlled by either providing a rate-controlling membrane or dispersing the compound in a polymer matrix or gel.
  • the invention also provides pharmaceutical products suitable for treatment of the eye.
  • Such pharmaceutical products include pharmaceutical compositions, devices and implants (which may be compositions or devices).
  • a pharmaceutical formulation for intraocular injection may comprise one or more compounds of the invention in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or non-aqueous solutions, suspensions or emulsions, which may contain antioxidants, buffers, suspending agents, thickening agents or viscosity-enhancing agents (such as a hyaluronic acid polymer).
  • suitable aqueous and nonaqueous carriers include water, saline (preferably 0.9%), dextrose in water (preferably 5%), buffers, dimethylsulfoxide, alcohols and polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like).
  • compositions may also contain adjuvants such as wetting agents and emulsifying agents and dispersing agents.
  • prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as polymers and gelatin.
  • injectable depot forms can be made by incorporating the drug into microcapsules or microspheres made of biodegradable polymers such as polylactide- polyglycolide. Examples of other biodegradable polymers include poly(orthoesters), poly(glycolic) acid, poly(lactic) acid, polycaprolactone and poly(anhydrides).
  • Depot injectable formulations are also prepared by entrapping the drug in liposomes (composed of the usual ingredients, such as dipalmitoyl phosphatidylcholine) or microemulsions which are compatible with eye tissue.
  • liposomes Composed of the usual ingredients, such as dipalmitoyl phosphatidylcholine
  • microemulsions which are compatible with eye tissue.
  • the rate of drug release from microcapsules, microspheres and liposomes can be controlled.
  • the compounds of the invention can also be administered surgically as an ocular implant.
  • a reservoir container having a diffusible wall of polyvinyl alcohol or polyvinyl acetate and containing a compound or compounds of the invention can be implanted in or on the sclera.
  • a compound or compounds of the invention can be incorporated into a polymeric matrix made of a polymer, such as polycaprolactone, poly(glycolic) acid, poly(lactic) acid, poly(anhydride), or a lipid, such as sebacic acid, and may be implanted on the sclera or in the eye. This is usually accomplished with the animal receiving a topical or local anaesthetic and using a small incision made behind the cornea. The matrix is then inserted through the incision and sutured to the sclera.
  • Topical pharmaceutical compositions suitable for application to the eye include solutions, suspensions, dispersions, drops, gels, hydrogels and ointments. See, e.g., U.S. Patent No. 5,407,926 and PCT applications WO 2004/058289, WO 01/30337 and WO 01/68053, the complete disclosures of all of which are incorporated herein by reference.
  • Topical formulations suitable for application to the eye comprise one or more compounds of the invention in an aqueous or nonaqueous base.
  • the topical formulations can also include absorption enhancers, permeation enhancers, thickening agents, viscosity enhancers, agents for adjusting and/or maintaining the pH, agents to adjust the osmotic pressure, preservatives, surfactants, buffers, salts (preferably sodium chloride), suspending agents, dispersing agents, solubilizing agents, stabilizers and/or tonicity agents.
  • Topical formulations suitable for application to the eye will preferably comprise an absorption or permeation enhancer to promote absorption or permeation of the compound or compounds of the invention into the eye and/or a thickening agent or viscosity enhancer that is capable of increasing the residence time of a compound or compounds of the invention in the eye.
  • an absorption or permeation enhancer to promote absorption or permeation of the compound or compounds of the invention into the eye and/or a thickening agent or viscosity enhancer that is capable of increasing the residence time of a compound or compounds of the invention in the eye.
  • exemplary absorption/permeation enhancers include methysulfonylmethane, alone or in combination with dimethylsulfoxide, carboxylic acids and surfactants.
  • Exemplary thickening agents and viscosity enhancers include dextrans, polyethylene glycols, polyvinylpyrrolidone, polysaccharide gels, Gelrite®, cellulosic polymers (such as
  • carboxyl-containing polymers such as polymers or copolymers of acrylic acid
  • polyvinyl alcohol and hyaluronic acid or a salt thereof are examples of carboxyl-containing polymers.
  • Liquid dosage forms ⁇ e.g., solutions, suspensions, dispersions and drops
  • a vehicle such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like, to form a solution, dispersion or suspension.
  • the pharmaceutical formulation may also contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, pH buffering agents and the like, for example sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc.
  • Aqueous solutions and suspensions suitable for treatment of the eye can include, in addition to a compound or compounds of the invention, preservatives, surfactants, buffers, salts (preferably sodium chloride), tonicity agents and water. If suspensions are used, the particle sizes should be less than 10 ⁇ to minimize eye irritation. If solutions or suspensions are used, the amount delivered to the eye should not exceed 50 ⁇ to avoid excessive spillage from the eye.
  • Colloidal suspensions suitable for treatment of the eye are generally formed from microparticles (i.e., microspheres, nanospheres, microcapsules or nanocapsules, where microspheres and nanospheres are generally monolithic particles of a polymer matrix in which the formulation is trapped, adsorbed, or otherwise contained, while with microparticles (i.e., microspheres, nanospheres, microcapsules or nanocapsules, where microspheres and nanospheres are generally monolithic particles of a polymer matrix in which the formulation is trapped, adsorbed, or otherwise contained, while with microparticles (i.e., microspheres, nanospheres, microcapsules or nanocapsules, where microspheres and nanospheres are generally monolithic particles of a polymer matrix in which the formulation is trapped, adsorbed, or otherwise contained, while with microparticles (i.e., microspheres, nanospheres, microcapsules or nanocapsules, where microspheres and nanospheres are generally monolithic particles of a
  • microcapsules and nanocapsules the formulation is actually encapsulated).
  • the upper limit for the size of these microparticles is about 5 ⁇ to about 10 ⁇ .
  • Ophthalmic ointments suitable for treatment of the eye include a compound or compounds of the invention in an appropriate base, such as mineral oil, liquid lanolin, white petrolatum, a combination of two or all three of the foregoing, or polyethylene- mineral oil gel.
  • a preservative may optionally be included.
  • Ophthalmic gels suitable for treatment of the eye include a compound or compounds of the invention suspended in a hydrophilic base, such as Carpobol-940 or a combination of ethanol, water and propylene glycol (e.g., in a ratio of 40:40:20).
  • a gelling agent such as hydroxylethylcellulose, hydroxypropylcellulose,
  • hydroxypropylmethylcellulose or ammoniated glycyrrhizinate is used.
  • a preservative and/or a tonicity agent may optionally be included.
  • Hydrogels suitable for treatment of the eye are formed by incorporation of a swellable, gel-forming polymer, such as those listed above as thickening agents or viscosity enhancers, except that a formulation referred to in the art as a "hydrogel” typically has a higher viscosity than a formulation referred to as a "thickened” solution or suspension.
  • a formulation may also be prepared so to form a hydrogel in situ following application to the eye.
  • Such gels are liquid at room temperature but gel at higher temperatures (and thus are termed “thermoreversible” hydrogels), such as when placed in contact with body fluids.
  • Biocompatible polymers that impart this property include acrylic acid polymers and copolymers, N-isopropylacrylamide derivatives and ABA block copolymers of ethylene oxide and propylene oxide
  • Dispersions may be liposomal, in which case the formulation is enclosed within liposomes (microscopic vesicles composed of alternating aqueous compartments and lipid bilayers).
  • Eye drops can be formulated with an aqueous or nonaqueous base also comprising one or more dispersing agents, solubilizing agents or suspending agents. Drops can be delivered by means of a simple eye dropper-capped bottle or by means of a plastic bottle adapted to deliver liquid contents dropwise by means of a specially shaped closure.
  • the compounds of the invention can also be applied topically by means of drug- impregnated solid carrier that is inserted into the eye.
  • Drug release is generally effected by dissolution or bioerosion of the polymer, osmosis, or combinations thereof.
  • matrix-type delivery systems can be used. Such systems include hydrophilic soft contact lenses impregnated or soaked with the desired compound of the invention, as well as biodegradable or soluble devices that need not be removed after placement in the eye.
  • These soluble ocular inserts can be composed of any degradable substance that can be tolerated by the eye and that is compatible with the compound of the invention that is to be administered.
  • Such substances include, but are not limited to, poly( vinyl alcohol), polymers and copolymers of polyacrylamide, ethylacrylate and vinylpyrrolidone, as well as cross-linked polypeptides or polysaccharides, such as chitin.
  • compositions include those suitable for ocular administration or for administration to the upper (nasal) or lower respiratory tract.
  • drops such as eye drops or nose drops
  • an aqueous or nonaqueous base also comprising one or more dispersing agents, solubilizing agents or suspending agents.
  • Liquid sprays are conveniently delivered from pressurized packs. Drops can be delivered by means of a simple eye dropper-capped bottle or by means of a plastic bottle adapted to deliver liquid contents dropwise by means of a specially shaped closure.
  • compositions of this invention suitable for parenteral
  • administrations comprise one or more VLC-PUFA compounds in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
  • aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
  • polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
  • vegetable oils such as olive oil
  • injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • compositions may also contain adjuvants such as wetting agents, emulsifying agents and dispersing agents. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like in the compositions.
  • isotonic agents such as sugars, sodium chloride, and the like in the compositions.
  • prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monosterate and gelatin.
  • Injectable depot forms are made by forming microencapsule matrices of the VLC-
  • biodegradable polymers such as polylactide-polyglycolide.
  • rate of drug release can be controlled.
  • biodegradable polymers include poly(orthoesters) and poly(anhydrides).
  • Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue. The injectable materials can be sterilized for example, by filtration through a bacterial-retaining filter.
  • the pharmaceutical formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampules and vials, and may be stored in a lyophilized condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use.
  • sterile liquid carrier for example water for injection
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the type described above.
  • Suitable antioxidant excipients may be selected from amongst one or more pharmaceutically acceptable antioxidants known in the art.
  • pharmaceutically acceptable antioxidants include butylated hydroxyanisole (BHA), sodium ascorbate, butylated hydroxytoluene (BHT), sodium sulfite, citric acid, malic acid and ascorbic acid.
  • BHA butylated hydroxyanisole
  • BHT butylated hydroxytoluene
  • the antioxidants may be present in the dosage formulations of the present invention at a concentration between about 0.001% to about 5%, by weight, of the dosage formulation.
  • Suitable chelating agents may be selected from amongst one or more chelating agents known in the art. Examples of suitable chelating agents include disodium edetate (EDTA), edetic acid, citric acid and combinations thereof.
  • the chelating agents may be present in a concentration between about 0.001% and about 5%, by weight, of the dosage formulation.
  • the dosage formulations provided by this invention may contain VLC-PUFAs either alone or in combination with other therapeutically active ingredients, and
  • pharmaceutically acceptable inert excipients includes at least one of diluents, binders, lubricants/glidants, coloring agents and release modifying polymers.
  • the dosage form may include one or more diluents such as lactose, sugar, cornstarch, modified cornstarch, mannitol, sorbitol, and/or cellulose derivatives such as wood cellulose and microcrystalline cellulose, typically in an amount within the range of from about 20%> to about 80%>, by weight.
  • diluents such as lactose, sugar, cornstarch, modified cornstarch, mannitol, sorbitol, and/or cellulose derivatives such as wood cellulose and microcrystalline cellulose, typically in an amount within the range of from about 20%> to about 80%>, by weight.
  • the dosage form may include one or more binders in an amount of up to about
  • binders include methyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinyl pyrrolidone, eudragits, ethyl cellulose, gelatin, gum arabic, polyvinyl alcohol, pullulan, carbomer, pregelatinized starch, agar, tragacanth, sodium alginate, microcrystalline cellulose and the like.
  • Suitable disintegrants include sodium starch glycolate, croscarmellose sodium, crospovidone, low substituted hydroxypropyl cellulose, and the like.
  • the concentration may vary from 0.1% to 15%, by weight, of the dosage form.
  • lubricants/glidants examples include colloidal silicon dioxide, stearic acid, magnesium stearate, calcium stearate, talc, hydrogenated castor oil, sucrose esters of fatty acid, microcrystalline wax, yellow beeswax, white beeswax, and the like.
  • concentration may vary from 0.1% to 15%, by weight, of the dosage form.
  • Coloring agents may be selected from the FDA approved colorants including, for example, Iron oxide, Lake of Tartrazine, Allura red, Lake of Quinoline yellow, Lake of Erythrosine.
  • Another embodiment of the invention relates to the use of any of the VLC-PUFA or compositions or formulations described herein in the preparation of a medicament for the treatment of inflammatory conditions, neurodegenerative disorders and macular or retinal disorders.
  • the invention now being generally described will be more readily understood by reference to the following example, which are included merely for the purposes of illustration of certain aspects of the embodiments of the present invention. The examples are not intended to limit the invention, as one of skill in the art would recognize from the above teachings and the following examples that other techniques and methods can satisfy the claims and can be employed without departing from the scope of the claimed invention.
  • triphenylphosphine (4.17 g, 15.9 mmol) in 4 portions with an interval of 15 min between in each portion. The resulting mixture was allowed to stir for 4 h at 0 °C. The reaction mixture was concentrated under reduced pressure. Hexane was added and the mixture was cooled and filtered to remove triphenylphosphine oxide. This process was repeated 2 more times to remove the majority of the byproduct. The crude product was then purified by flash column chromatography using hexanes to 8% ether in hexanes to obtain pure DHA bromide.
  • a stock solution of H 5 IOe/Cr0 3 was prepared by dissolving H5I06 (5.7 g, 25 mmol) and Cr0 3 (12 mg, 1.2 mol %) in wet MeCN (0.75 v % water) to a volume of 55.7 mL (complete dissolution in about 1.5 hours).
  • the H 5 IOe/Cr0 3 solution (1.2 mL) was then added to a solution of the C28:6 alcohol (42 mg, 0.15 mmol) in wet acetonitrile (1.0 mL, 0.75 v % water) slowly while maintaining the reaction temperature at 0-5 °C.
  • the mixture was allowed to stir at 0°C for 0.5 h and the completion of the reaction was confirmed by TLC assay.
  • triphenylphosphine (461 mg, 1.76 mmol) in one portion.
  • the reaction mixture was allowed to stir at 0 to 10 °C for 18 h.
  • the reaction mixture was then concentrated under reduced pressure and purified by flash column chromatography to obtain 265 mg of desired product.
  • the C34:6 VLC PUFA will be synthesized as shown above by following the process for the synthesis of C28:6 VLC PUFA described earlier.
  • DHA bromide was prepared as described in Example 1. 6- tetrahydropyranyloxyhexyl magnesium chloride was prepared as follows: 1 ,2-dibromoethane
  • thermometer thermometer, addition funnel and a water condenser was charged with magnesium
  • reaction mixture was allowed to reflux for 90 min to obtain 6- tetrahydropynyloxyhexyl magnesium chloride.
  • H 5 I0 6 (11.4 g) and Cr0 3 (23 mg) was dissolved in wet ACN (0.75 v% H 2 0). 25 mL 3 necked round bottomed flask attached with a thermometer and an addition funnel was charged with C28:5 alcohol (500 mg, 1.25 mmol). 0.75 v% wet THF (10 mL) was added via a syringe. The mixture was cooled to 0 °C (ice-water bath). To this mixture was added HsIC CrOs stock solution (35 mL) dropwise at such a rate that the temperature does not rise above 5 °C.
  • thermometer, a water condenser and an addition funnel was charged with C28:6 bromide (7.50 g, 16.3 mmol).
  • the flask was evacuated and filled with N 2 .
  • Anhydrous THF (30 mL) was added via a syringe and the mixture was heated to 60 °C.
  • a solution of Li 2 CuCl 4 (4.9 mL of 0.1 M solution in THF, 0.49 mmol) was added dropwise via a syringe. After 10 min N-methyl-2-pyrrolidone (6.3 mL, 65.2 mmol) was added and the mixture was allowed to stir at reflux temperature.
  • thermometer was charged with C34:6 acid (3.0 g, 6.05 mmol). Anhydrous THF (30 mL) was added and the mixture was allowed to cool to °C (ice-water bath). N,N- dimethylamino pyridine (0.81 g, 6.7 mmol) was added in one portion. After 10 min absolute ethanol (3.5 mL, 60.5 mmol) was added via a syringe. After 10 min EDC.HCl (1.7 g, 9.1 mmol) was added in one portion and the mixture was allowed to stir at 0 to 5 °C for 45 min. The cold bath was removed and the mixture was allowed to warm to room temperature and stir at that temperature for 4 h.
  • triphenylphosphine oxide This process was repeated 2 more times to remove majority of the byproduct.
  • the crude product was then purified by flash column chromatography using hexanes to obtain 157 g of the product (90% yield).
  • 1,2-dibromoethane (2.1 mL, 22.8 mmol) was added via a syringe. After 10 min the remaining solution from the addition funnel was added dropwise over a period of 30 min. The reaction mixture was allowed to reflux for 90 min to obtain 8-tetrahydropyranyloxyoctyll magnesium chloride. Coupling Reaction of EPA bromide with 8-tetrahydropyranyloxyoctyl magnesium chloride catalyzed by Li 2 CuCLi:
  • VLC-PUFAs The accumulation of VLC-PUFAs in different tissues was assessed in animals fed ethyl esters of VLC-PUFAs.
  • Each animal tissue tested (Brain, Heart, Liver, Testis, Eyes) was dissected for further analysis after euthanasia.
  • the tissues were frozen and weighed and then homogenized.
  • the organic phase was extracted with methanol/chloroform, dried by evaporation, resuspended in acetonitrile/HCl and hexane.
  • the lipophilic hexane layer was recovered, dried by evaporation and resuspended in acetone.
  • the acetone solution, containing the biological extract, was derivatized with 3-Carbinol Pyridinium and 3 Bromo Pyridinium (see Yang et. al Anal. Chem. 79:5150-5157, 2007).
  • the samples were added with a deuterated reference standard, obtained via derivatization of standard reference VLC-PUFA 34:5 and 34:6 with N-CD3-3-carbinol pyridinium.
  • the standards, 34:5 and 34:6 PUFAs were desolved in acetone (0.01 mg/ml) and derivatized using the deuterated reagents (D3-Carbinol
  • the VLC-PUFAs 34:5 and 34:6 and their corresponding deuterated standards were measured within the same 15 minutes chromatographic runs.
  • the retention time for 34:6 (detected at m/z 602, standard deuterated at m z 605) is 7.6 min, while the 34:5 (detected at m z 604, standard deuterated at m z 607) is 10.3 minutes.
  • the semi-quantitative assessment of the VLC-PUFA is calculated from the ratio between the areas of the peaks of the 34:6 and its correspondent deuterated standard (D3-34:6) and from the area of 34:5 and its corresponding deuterated standard (D3-34:5).
  • Figure 11 shows the HPLC-MS analysis of 34:6 and D3-34:5 monitored selectively in channels 602 and 605
  • Figure 12 shows the HPLC-MS analysis of 34:5 and D3-34:5 monitored selectively in channels 604 and 607.
  • the amount of deuterated standard spiked in each sample is defined (in this case 250 ng were spiked in each sample) allowing a semi-quantitative assessment of the endogenous levels of VLC PUFA present in the sample.
  • Figure 13 provides a visual comparison of the amount of 34:6 and 34:5 present in homogenates from liver for each animal in the three experimental groups. Basal levels (untreated animals) are close to the detection limit. However, the accumulation of the VLC-PUFA after 10 days treatment is evident.
  • Figure 14 provides a visual comparison of the amount of 34:6 and 34:5 present in homogenates from testis for each animal in the three experimental groups. Basal levels (untreated animals) are close to, or below the detection limit. As seen for the liver homogenates samples, the accumulation of the VLC-PUFA after 10 days treatment is evident. C. EYE
  • Figure 15 provides a visual comparison of the amount of 34:6 and 34:5 present in homogenates from eyes from each animal in the three experimental groups. While the levels of these two VLC-PUFAs in the eye are well above the detection limit,
  • Figure 16 provides a comparison of the amount of 34:6 and 34:5 present in homogenates from heart for each animal in the three experimental groups. Basal levels (untreated animals) are close or below detection limit. As seen for homogenate samples obtained from liver and testis, the accumulation of the administered VLC-PUFA after 10 days treatment is evident.
  • Figure 17 shows the accumulation of the 34:6 and 34:5 VLC-PUFAs present in the plasma of treated animals. Accumulation of the VLC-PUFAs is evident only in the treated animals. (Group #2 received the 34:5 ester while Group#3 received the 34:6 ester)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des procédés permettant de synthétiser des acides gras polyinsaturés à très longue chaîne (VLC-PUFA, C28-C42:4,5 et 6) oméga-3 et oméga-6, des analogues et des dérivés de ceux-ci, des compositions pharmaceutiques contenant ces composés VLC-PUFA isolés et leurs utilisations thérapeutiques.
PCT/US2010/054901 2009-10-31 2010-10-31 Synthèse et utilisation d'acides gras polyinsaturés à très longue chaîne (vlc-pufa) oméga-3 et oméga-6 WO2011053892A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/460,536 US20130190399A1 (en) 2009-10-31 2012-04-30 Synthesis and use of omega-3 and omega 6 very long chain polyunsaturated fatty acids (VLC-PUFA)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25696909P 2009-10-31 2009-10-31
US61/256,969 2009-10-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/460,536 Continuation-In-Part US20130190399A1 (en) 2009-10-31 2012-04-30 Synthesis and use of omega-3 and omega 6 very long chain polyunsaturated fatty acids (VLC-PUFA)

Publications (1)

Publication Number Publication Date
WO2011053892A1 true WO2011053892A1 (fr) 2011-05-05

Family

ID=43922607

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/054901 WO2011053892A1 (fr) 2009-10-31 2010-10-31 Synthèse et utilisation d'acides gras polyinsaturés à très longue chaîne (vlc-pufa) oméga-3 et oméga-6

Country Status (1)

Country Link
WO (1) WO2011053892A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018175288A1 (fr) 2017-03-20 2018-09-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Acides gras polyinsaturés à chaîne très longue, dérivés hydroxylés d'elovanoid, et procédés d'utilisation
NO20180849A1 (en) * 2018-06-19 2019-12-20 Epax Norway As Composition for treatment of dry eye disease and meibomianitis
WO2022015699A1 (fr) * 2020-07-14 2022-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procédés de production d'acides gras à très longue chaîne
WO2022047365A1 (fr) * 2020-08-31 2022-03-03 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Procédés de production d'acides gras à très longue chaîne (vlcfa)
WO2022168958A1 (fr) 2021-02-05 2022-08-11 日本水産株式会社 Composition d'acide gras polyinsaturé à chaîne ultra-longue
WO2022199378A1 (fr) * 2021-03-20 2022-09-29 上海鼎雅药物化学科技有限公司 Procédé de synthèse d'un principe actif pharmaceutique d'acide bempédoïque
WO2024005039A1 (fr) * 2022-06-28 2024-01-04 株式会社ニッスイ Procédé de fabrication d'acide gras polyinsaturé à chaîne très longue

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422371A (en) * 1992-05-27 1995-06-06 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
US20090203787A1 (en) * 2008-01-28 2009-08-13 Anderson Robert E Very long chain polyunsaturated fatty acids, methods of production, and uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422371A (en) * 1992-05-27 1995-06-06 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
US20090203787A1 (en) * 2008-01-28 2009-08-13 Anderson Robert E Very long chain polyunsaturated fatty acids, methods of production, and uses

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018175288A1 (fr) 2017-03-20 2018-09-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Acides gras polyinsaturés à chaîne très longue, dérivés hydroxylés d'elovanoid, et procédés d'utilisation
KR20230164772A (ko) * 2018-06-19 2023-12-04 이팍스 노르웨이 에이에스 안구 건조 질환 및 마이봄선염의 치료를 위한 조성물
AU2019288931B2 (en) * 2018-06-19 2023-05-04 Epax Norway As Composition for treatment of dry eye disease and meibomianitis
CN112351776A (zh) * 2018-06-19 2021-02-09 艾帕克斯挪威联合股份有限公司 用于治疗干眼病和睑板腺炎的组合物
NO345574B1 (en) * 2018-06-19 2021-04-26 Epax Norway As Composition for treatment of dry eye disease and meibomianitis
JP2021529167A (ja) * 2018-06-19 2021-10-28 エーパックス ノルウェー アクスイェ セルスカプ ドライアイ疾患及び瞼板腺炎の治療のための組成物
US20210361606A1 (en) * 2018-06-19 2021-11-25 Epax Norway As Composition for treatment of dry eye disease and meibomianitis
WO2019245382A1 (fr) * 2018-06-19 2019-12-26 Epax Norway As Composition destinée au traitement du syndrome de l'œil sec et de la meibomite
US11992474B2 (en) 2018-06-19 2024-05-28 Epax Norway As Composition for treatment of dry eye disease and meibomianitis
KR102665229B1 (ko) 2018-06-19 2024-05-13 이팍스 노르웨이 에이에스 안구 건조 질환 및 마이봄선염의 치료를 위한 조성물
NO20180849A1 (en) * 2018-06-19 2019-12-20 Epax Norway As Composition for treatment of dry eye disease and meibomianitis
WO2022015699A1 (fr) * 2020-07-14 2022-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procédés de production d'acides gras à très longue chaîne
WO2022047365A1 (fr) * 2020-08-31 2022-03-03 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Procédés de production d'acides gras à très longue chaîne (vlcfa)
WO2022168958A1 (fr) 2021-02-05 2022-08-11 日本水産株式会社 Composition d'acide gras polyinsaturé à chaîne ultra-longue
WO2022199378A1 (fr) * 2021-03-20 2022-09-29 上海鼎雅药物化学科技有限公司 Procédé de synthèse d'un principe actif pharmaceutique d'acide bempédoïque
WO2024005039A1 (fr) * 2022-06-28 2024-01-04 株式会社ニッスイ Procédé de fabrication d'acide gras polyinsaturé à chaîne très longue

Similar Documents

Publication Publication Date Title
US20130190399A1 (en) Synthesis and use of omega-3 and omega 6 very long chain polyunsaturated fatty acids (VLC-PUFA)
AU2008269989B2 (en) Production and purification of esters of polyunsaturated fatty acids
ES2857173T3 (es) Aceites microbianos enriquecidos en ácidos grasos poliinsaturados
WO2011053892A1 (fr) Synthèse et utilisation d'acides gras polyinsaturés à très longue chaîne (vlc-pufa) oméga-3 et oméga-6
RU2509071C2 (ru) Новые липидные соединения
EP2918278A1 (fr) Extraits d'algues contenant de la fucoxanthine et du fucoxanthinol
KR20180100714A (ko) 에이코사펜타엔산 생산 미생물, 지방산 조성물 및 이의 제조방법 및 용도
AU2020200796B2 (en) Novel n-3 immunoresolvents: structures and actions
US20100266681A1 (en) Fatty acid alcohols
JP7259034B2 (ja) 超長鎖脂肪酸組成物
KR20190104633A (ko) 지방산 조성물
JP2010508261A (ja) 新規脂質化合物
EP0635266A1 (fr) Composition comprenant un acide gras insaturé de la série oméga 9 pour le traitement des symptomes provoqués par les leucotriènes B4
EP1231213B1 (fr) Procédé de préparation des phosphatides et leur utilisation dans les domaines cosmétique, pharmaceutique et alimentaire
JP6806339B2 (ja) 新規なトリグリセリド及びその用途
JP6806340B2 (ja) １０−ヒドロキシ−シス−１２−オクタデセン酸アルキルエステル及びその用途
KR20170005886A (ko) 아스타잔틴 모노에스터의 제조방법
US20020155558A1 (en) Procedure for the preparation of pure phosphatides and their use in the cosmetic, pharmaceutical and alimentary fields
JP2020092697A (ja) オキソ脂肪酸組成物及び製造方法
JP2002205953A (ja) 抗腫瘍組成物
JP2020079278A (ja) アポｃ３を低下させるためのチアオキソ化合物の使用
WO2005005367A1 (fr) Acide gras de synthese chimique a insaturation elevee
KR20150134828A (ko) 아스타잔틴 모노에스터의 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10827592

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10827592

Country of ref document: EP

Kind code of ref document: A1